Takeda Philippines
Country Leadership Team (Seated
from L to R) Sheryll Anne Corpuz, Estela del Rosario, Loreann Villanueva,
Arabella Benito, Armi Grace Gonzales
|
(Standing From L to R)
John Raymond Gulinao, Fatima Mangalindan, Rommel Velasco, Joy Althea Pabellon,
Freddie Deinla |
Takeda Philippines
Healthcare, Inc. (“Takeda”), a
leading pharmaceutical company committed to create better health for people and
a brighter future for the world, has been recognized with two prestigious
awards at the Asia Responsible Enterprise Awards (AREA) ceremony held in
Cambodia.
The first award was
given to Takeda's Access To Medicines: Patient Assistance Program (AtM Program)
in the Health Promotion category. Rooted in the vision of broadening access to
life-changing medicines and vaccines in underserved communities, the AtM
Program utilizes an integrated and sustainable approach that mobilizes the
collective efforts of all involved stakeholders.
Focusing on
diseases with the highest unmet need such as cancer and rare diseases, Takeda
strives to bring its innovative and high-quality medicines to patients in the
Philippines who have limited access to healthcare services. Through this
program, the company has successfully provided financial assistance to over 600
patients nationwide, ensuring they receive crucial treatments regardless of
their capacity to pay.
The AtM Program
involves multi-stakeholder collaboration to address the pain points in the
patient’s journey in the areas of disease awareness, accurate diagnosis, and
appropriate treatment, support, and care. Based on Takeda’s insights on
Filipino patients, it takes them about 5 to 10 visits to different doctors
before they are properly diagnosed. Thus, the “Spot Lymphoma, Stop Lymphoma”
campaign was launched together with 5 major medical societies and 2
non-government organizations to educate patients. Takeda in partnership with
Philippine Cancer Society (PCS) provided CD30 screening through 24 hospitals
majority of which are located outside of the capital of Metro Manila so
patients would have access to CD30 screening.
Aside from
screening, a series of workshops with Philippine Pathologists in partnership
with medical societies were done to increase the skills and confidence of
pathologists in utilizing immunohistochemistry and ensure early and proper
diagnosis. The cornerstone of Takeda’s
access program in the country is the Patient Assistance Program (PAP). This
unique and innovative affordability-based program enabled more than 600
patients regardless of their socio-economic class to access their treatment
with Takeda’s target therapy at a price that is based on the patient’s
financial capacity to pay.
Takeda also partnered with an NGO to provide a series
of training to oncology nurses to enrich their capability in educating
patients. They also provided a grant to the Cancer Care
Registry and Research Philippines Foundation (CARE PH) to expand its cancer registry and research.
Finally, as a
culmination of Takeda’s holistic initiatives in 2022, the Access to Medicines
(ATM) Summit gathered 137 multi-sectoral stakeholders from 42 organizations for
a 2-day meeting, and discussed how each can support healthcare strengthening in
the Philippines. Takeda’s framework is to build sustainable
capacity at every stage from diagnosis to ongoing patient support. To date,
more than 1,700 pathologists, 6,997 oncology and 5,683 endoscopy nurses, 4
medical societies, and 7 NGOs and patient organizations have partnered with
Takeda in these endeavors.
The second award
recognized Takeda for its unwavering dedication to employee well-being and
engagement in the Investment in People category. These programs aim to foster a
healthy and collaborative working environment, enabling employees to thrive
personally and professionally.
From
L-R: Joanna Noor, Sheryll Corpuz, Dr. Felycette Gay Lapus, Dr. Arielle
Severino, and Caroline Ramira during the 2022 Philippine Society of
Medical Oncology (PSMO) Annual Convention.
Takeda's employee
well-being and engagement programs encompass diverse wellness initiatives and
engagement activities that encourage a robust and motivated workforce. From the
Partnerships for Growth (PFG) mentoring program, Lunch and Learn sessions, to
career development and energy management workshops, Takeda invests in its
employees' growth and development. These engagement efforts cultivate open
communication, collaborative relationships, and contribute to the company's
talent development and retention strategies, resulting in sustained high
engagement levels with an average of 92% in the last two years of the company’s
annual engagement survey.
Takeda's dedication
to its employees has also led to the prestigious Great Place to Work®
certification for two consecutive years, as well as one of 2023 Philippines
Best Workplaces. The company remains steadfast in ensuring its programs cater
to the needs of its workforce, empowering them to flourish and reach their full
potential.
"We are
honored to receive these recognitions as it cements Takeda’s enduring
commitment to serve communities as well as our employees," Loreann Villanueva,
Country Manager of Takeda Healthcare Philippines Inc. said. "These awards
inspire us to push the boundaries further, making a lasting difference to the
Filipino community through an empowered and highly dedicated workforce."
AREA recognizes and
honors deserving Asian businesses for championing sustainable and responsible
business practices in the following categories: Green Leadership, Social
Empowerment, Health Promotion, Investment in People, Corporate Governance,
Circular Economy Leadership, Corporate Sustainability Reporting and Responsible
Business Leadership.
Takeda Healthcare
Philippines Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company
Limited, a global R&D-driven biopharmaceutical company. Its headquarters in
Makati City are home to Takeda Philippines’ employees who all share the same
passion, drive, and commitment towards delivering life-transforming treatments,
and sustainable patient access programs.
To learn more about
Takeda and its initiatives, please visit www.takeda.com.
About Takeda
Takeda
is focused on creating better health for people and a brighter future for the
world. We aim to discover and deliver life-transforming treatments in our core
therapeutic and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Together with our partners, we aim to improve the patient experience and
advance a new frontier of treatment options through our dynamic and diverse
pipeline. As a leading values-based, R&D-driven biopharmaceutical company
headquartered in Japan, we are guided by our commitment to patients, our people
and the planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have defined us for
more than two centuries.
Takeda
Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda
Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient
access to treatment across the country through sustainable access programs
enabling affordable and integrated access solutions for disease areas such as
oncology, gastroenterology, rare diseases & vaccines and by strengthening
the healthcare system guided by our commitment to Patients, our People and the
Planet.
For more information, visit https://www.takeda.com.
.png)
.png)
%20(1).png)
